WO2023148527 - SELF-REPLICATING RNA AND USES THEREOF
National phase entry:
Publication Number
WO/2023/148527
Publication Date
10.08.2023
International Application No.
PCT/IB2022/051021
International Filing Date
07.02.2022
Title **
[English]
SELF-REPLICATING RNA AND USES THEREOF
[French]
ARN AUTORÉPLIQUANT ET UTILISATIONS ASSOCIÉES
Applicants **
SEQIRUS INC.
Inventors
ALLEN, Pirada
DE SOUZA, Ivna
WEN, Yingxia
CHANG, Cheng
LEE, Changkeun
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
USPTO
* |
| * | |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2704 | |
| EPO | Filing, Examination, Granting | 19940 | |
| Japan | Filing, Examination, Granting | 2618 | |
| South Korea | Filing, Examination, Granting | 2923 | |
| USA | Filing, Examination, Granting | 9110 |
Total:
37,295
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present disclosure relates to self-replicating RNA encoding an antigen from severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2) and uses thereof. Specifically, the disclosure provides a self-replicating RNA or a monocistronic self-replicating RNA comprising a nucleotide sequence encoding an antigen operably linked to a'subgenomic promoter, wherein the antigen is from SARS-CoV-2, and is a spike (S) protein or a nucleocapsid (N) protein.[French]
La présente divulgation concerne un ARN autorépliquant codant pour un antigène du coronavirus 2 du syndrome respiratoire aigu sévère (SARS-CoV-2) et des utilisations associées. Spécifiquement, la divulgation concerne un ARN autorépliquant ou un ARN autorépliquant monocistronique comprenant une séquence nucléotidique codant pour un antigène lié de manière fonctionnelle à un promoteur subgénomique, l'antigène provenant du SARS-CoV-2 et étant une protéine spike (S) ou une protéine de nucléocapside (N).